Can intercalating chemotherapy with epidermal growth factor receptor inhibitors delay development of treatment resistance in advanced non-small cell lung cancer?

References

• Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Supplement 5):v1–v27.
   PubMedGoogle Scholar
• Batson S, Mitchell SA, Windisch R, et al. Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis. Onco Targets Ther. 2017 May;5(10):2473–2482.
   Google Scholar
• Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15:1236–1244.
   PubMed Web of Science ®Google Scholar
• Zhang K, Yuan Q. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer. J Cancer Res Ther. 2016;12(Supplement):C131–C137.
   PubMedGoogle Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2017;376(7):629–640.
   PubMed Web of Science ®Google Scholar
• Minari R, Bordi P, Tiseo M. Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance. Transl Lung Cancer Res. 2016;5(6):695–708.
   PubMed Web of Science ®Google Scholar
• Lee CK, Man J, Lord S, et al. Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer—a meta-analysis. J Thorac Oncol. 2016;12(2):403–407.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5892–5899.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol. 2004;22:785–794.
   PubMed Web of Science ®Google Scholar
• Oizumi S, Sugawara S, Minato K, et al. Updated survival outcomes of NEJ005/TCOG0902, a randomized phase II study of concurrent (C) versus sequential alternating (S) gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations. J Clin Oncol. 2017;35(suppl):abstr 9038.
   Google Scholar
• Inoue A, Hosomi Y, Maemondo M, et al. Phase III study comparing gefitinib with gefitinib combined with carboplatin/pemetrexed for advanced non-small cell lung cancer with EGFR mutation (NEJ009). J Clin Oncol. 2014;32(15_suppl). DOI:10.1200/jco.2014.32.15_suppl.tps8131
   PubMed Web of Science ®Google Scholar
• Cheng Y, Murakami H, Yang P-C, et al. Randomized Phase II trial of Gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non – small-cell lung cancer with activating epidermal growth factor receptor mutations. J Clin Oncol. 2016;34(27):3258–3266.
   PubMed Web of Science ®Google Scholar
• Davies AM, Ho C, Lara PN Jr, et al. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer. 2006;7:385–388.
   PubMed Web of Science ®Google Scholar
• Soria JC, Yl W, Nakagawa K, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16(8):990–998.
   PubMed Web of Science ®Google Scholar
• Li T, Ling YH, Goldman ID, et al. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res. 2007;13:3413–3422.
   PubMed Web of Science ®Google Scholar
• La Monica S, Madeddu D, Tiseo M, et al. Combination of gefitinib and pemetrexed prevents the acquisition of TKI resistance in NSCLC cell lines carrying EGFR-activating mutation. J Thorac Oncol. 2016;11(7):1051–1063.
   PubMed Web of Science ®Google Scholar
• Cheng H, An SH, Zhang XC, et al. In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. Cancer Chemother Pharmacol. 2011;67:637–646.
   PubMed Web of Science ®Google Scholar
• Dal Bello MG, Alama A, Barletta G, et al. Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors. Int J Cancer. 2015;137:2947–2958.
   PubMed Web of Science ®Google Scholar
• Tsai CM, Chiu CH, Chang KT, et al. Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation. J Thorac Oncol. 2012 Aug;7(8):1218–1227.
   PubMed Web of Science ®Google Scholar
• Tsai CM, Chen JT, Chiu CH, et al. Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib. Lung Cancer. 2013;82:305–312.
   PubMed Web of Science ®Google Scholar
• La Salvia A, Rossi A, Galetta D, et al. Intercalated chemotherapy and epidermal growth factor receptor inhibitors for patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer. 2017;18(1):23–33.
   PubMed Web of Science ®Google Scholar
• Rossi A, La Salvia A, Di Maio M. Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer. Expert. Rev Respir Med. 2017;11(3):171–180.
   Google Scholar
• Zwitter M, Rossi A, Di Maio M, et al. Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors. Radiol Oncol. 2017 18;51(3):241–251.
   PubMed Web of Science ®Google Scholar
• Kanda S, Ohe Y, Horinouchi H, et al. Phase ΙΙ study of gefitinib and inserted cisplatin plus docetaxel as a first-line treatment for advanced non-small cell lung cancer harboring an epidermal growth factor receptor activating mutation. J Clin Oncol. 2013;31(suppl):abstr 8064.
   Google Scholar